

















Extended Data Figure 1





Extended Data Figure 2



Extended Data Figure 3




Extended Data Figure 4




Neoadjuvant RNA-LPA


Post-adjvant MR



c



e




Extended Data Figure 5


a

Group	Total Number of Animals (Sex)	Subgroup (Termination)	Test Article	Route
1	10 (5M/5F)	1a (35±1 days)	Vehicle	i.v.
	10 (5M/5F)	1b (56±2 days)		
	10 (5M/5F)	1c (112±3 days)		
2	10 (5M/5F)	2a (35 ± 1 days)	LP	i.v.
	10 (5M/5F)	2b (56±2 days)		
	10 (5M/5F)	2c (112±3 days)		
3	10 (5M/5F)	3a (35±1 days)	RNA-LPA (low)	i.v.
	10 (5M/5F)	3b (56±2 days)		
	10 (5M/5F)	3c (112±3 days)		
4	10 (5M/5F)	4a (35 ± 1 days)	RNA-LPA (High)	i.v.
	10 (5M/5F)	4b (56±2 days)		
	10 (5M/5F)	4c (112±3 days)		

b




c




Extended Data Figure 6

a




b




Extended Data Figure 7

a



b



Extended Data Figure 8

